New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 25, 2014
16:02 EDTAUXL, BSTCBioSpecifics announces filing by Sobi for EU approval of XIAPEX
BioSpecifics Technologies (BSTC) announced today that Swedish Orphan Biovitrum AB, or Sobi, has filed for an extension of the label for XIAPEX with the European Medicines Agency to include the indication of Peyronie's disease. XIAPEX is currently approved for the treatment of Dupuytren's contracture in adult patients with a palpable cord. BioSpecifics' partner, Auxilium Pharmaceuticals (AUXL), is partnered with Sobi for the marketing of XIAPEX in 71 Eurasian and African countries for the treatment of Dupuytren's contracture, and Peyronie's disease pending applicable regulatory approvals.
News For BSTC;AUXL From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 23, 2015
07:50 EDTBSTCBioSpecifics management to meet with Deutsche Bank
Meeting to be held in New York on February 23 hosted by Deutsche Bank.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use